63 results about "Cholecystokinin" patented technology

A complex is provided for the treatment of neurogenic conditions having the formula: where R1 is M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium (II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium (II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium (II):transporter ligand.

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged cartilage and subchondral bone. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of cartilage and bone damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

A compound is provided that has the formula NH2CH2CH2CH2C(O)N—R   (I) where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound is provided that has the formula NH2CH2CH2CHR1C(O)N—R  (I) where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

The present invention relates to formulations and methods for weight management utilizing processed Morinda citrifolia products or extracts. Specifically, the present invention relates to formulations, which may be used for weight loss, regulating gastric motility and regulating plasma levels of cholecystokinin.

A complex is provided for the treatment of neurogenic conditions having the formula:where R1 isM is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium(II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium(II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium(II):transporter ligand.

A compound is provided that has the formulaNH2CH2CH2CH2C(O)N—R  (I)where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound is provided that has the formulaNH2CH2CH2CHR1C(O)N—R   (I)where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged ligaments. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of ligaments damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

A compound of the formula where R1 is H, C1-C4 alkyl and OH; R2 in is H, C1-C4 alkyl and OH; R3 is H and C1-C4 alkyl; R4 is H and C1-C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2-C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdominal pain in a mammal. The methods include administering to the mammal a non-pancreatic protease or a composition comprising a non-pancreatic protease. The methods of this invention are particularly useful for treating abdominal pain in a mammal suffering from acute or chronic pancreatitis and related conditions.

A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.

The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) releasing activity that can be used to promote satiety.

Pharmaceutical, nutraceutical, dietetic and nutritional compositions containing:a) glucomannan,b) Opuntia ficus indica, c) microcrystalline cellulosepresent a high gastrointestinal swelling index, which induces an immediate feeling of fullness, release of cholecystokinins and slowing of gastric voiding that prolongs the feeling of fullness. Associating the complex of three vegetable fibers with a mixture of freeze-dried mucilages increases its gastrointestinal swelling properties.

The invention relates to a meal replacement bar capable of reducing weight and a preparation method of the meal replacement bar. According to the meal replacement bar capable of reducing weight, a potato extract is added for the first time, and the raw materials of the meal replacement bar comprise a protease inhibitor (PI2), so that release of cholecystokinin (CCK) can be promoted, and natural satiety can be provided. The meal replacement bar capable of reducing weight is prepared by an advanced cold mixing technology and is different from a convention meal replacement bar capable of reducingweight; a technology of the conventional meat replacement bar lies in that syrup needs to be heated and then cooled, and then finished products are made under the baking condition; and the meal replacement bar disclosed by the invention lies in that mixing, shaping and dicing are directly performed at normal temperature, so that light deformation caused by thermal expansion and cold contraction of the syrup is avoided, and besides, the loss of self nutrient components of products in the heating process and in the baking process is avoided.

The invention relates to a food composition used for controlling body weight and a preparation method thereof. The food composition comprises the ingredients according to weight percentage: 10-50% of coixseed powder, 5-30% of corn flour, 0.5-10% of red jujube powder, 1-20% of pine nut powder, 10-40% of whey protein concentrate powder, 5-35% of crystal line fructose, 1-10% of dried egg yolk, 0.5-10% of konjaku flour, 5-30% of cornmeal, 0.05-0.8% of vitamin composite powder, 0.8-3% of mineral composition composite powder and 0.1-1.5% of silicon dioxide. The preparation steps comprise all the ingredients are weighed according to the weight percentage and gradually mixed together. The composition is prepared by combining natural plant extracts and modern technology, and can enhance the 'satiety' by increasing the release of cholecystokinin (CCK) and glucagon (GLP) which are naturally secreted by the human body; meanwhile, right amount of dietary fiber having multiple sources can be added into the composition, so that gastric mucosa is protected and stomach has certain shrink space, thus the composition is good for controlling the body weight for a long time; furthermore, the composition also strengthens and supplements multiple vitamins and mineral compositions that are necessary for the human body in the daily life, so that the process of controlling the body weight is safer and has more remarkable effect.

A method of increasing fasting levels of cholecystokinin in a subject by the administration of potato proteinase inhibitor II is described. A method for extending satiety in a subject with elevated fasting cholecystokinin levels due to treatment is also described, along with a method of identifying subjects likely to respond to treatment.

The present invention provides protein hydrolysate compositions having enhanced cholecystokinin (CCK) and / or giuoagon-like peptide-1 (GLP-1) releasing activity and food forms incorporating the protein hydrolysate compositions, which can be used to promote satiety.

The invention discloses yolk powder containing double-titer yolk antibody (Immunoglobulin yolk, IgY) of cholecystokinin / intestinal bacterial urease. A preparation method of the yolk powder comprises the following steps: 1) preparing vaccine by mixing purified cholecystokinin 39 peptide (CCK39) / urease B subunit (UreB) fusion protein with Freund's adjuvant well, immunizing healthy laying hens, determining yolk IgY titer through enzyme-linked immunosorbent assay and collecting hyperimmune eggs; and 2) separating yolk from hyperimmune eggs and preparing the yolk into yolk powder. The yolk powder containing double-titer IgY, which is prepared by the method, is added to feed for feeding pigs, and the satiety of the pigs is not produced or delayed due to CCK in the IgY and secreted by porcine intestinal canals so as to increase feed intake. The IgY can also neutralize urease secreted by intestinal bacteria so as to reduce the production of ammonia, protect porcine intestinal canals and respiratory tract, reduce the waste of feed protein and improve culture environment.

The invention provides compositions and methods for characterizing appetite regulation in a subject. In one embodiment, the composition comprises a solid support comprising probes for measuring a biomarker panel comprising, for example, total ghrelin, obestatin, cholecystokinin, GLP-1(6-37)-NH2, NPY and α-MSH. The simultaneous use of multiple biomarkers with independent classification power will increase the performance of the biomarker panel in characterizing appetite regulation. The invention also provides methods of treating a subject (e.g. one experiencing obesity) and determining the efficacy of a therapy through assaying the various biomarkers of a biomarker panel disclosed herein.

The invention discloses feed active egg powder with nutrition, healthcare and growth promotion functions and a production method thereof, wherein the feed active egg powder with nutrition, healthcare and growth promotion functions is obtained by fully mixing weighed enterotoxin-resistant Escherichia coli tetravalent yolk antibody, C-type clostridium perfringens and beta toxoid-resistant divalent yolk antibody, rotavirus-resistant yolk antibody, transmissible gastroenteritis and epidemic diarrhea-resistant bigeminal yolk antibody, cholecystokinin / somatostatin-resistant double-fusion white and yolk antibody, lysozyme meringue powder, epidermal growth factor-containing meringue powder, common meringue powder and silica (antitackiness agent) for 60 to 100 seconds. The feed active egg powder with nutrition, healthcare and growth promotion functions provided by the invention has the beneficial effects of containing high-quality protein, fat and amino acid required for the growth and development of piglets, containing lysozyme, yolk antibody and epidermal growth factor for preventing disease, protecting health and promoting growth, and having four efficacies of enhancing the feed intake,accelerating the growth, boosting the immunity and controlling the diarrhea of the piglets before and after weaning.

The invention discloses a meal replacement composition with a weight-losing function. The meal replacement composition is prepared from the following components: 25 to 80 parts of protein powder, 5 to40 parts of psyllium seed husk powder, 0.1 to 5 parts of black ginger extract, 0.1 to 5 parts of white kidney bean extract and 1 to 30 parts of pine seed oil micro-capsule powder. According to the composition provided by the invention, the effects of losing weight and losing lipid can be effectively realized and the composition can have a certain regulation effect on body metabolism. Pine seed oil in the composition provided by the invention contains rich pinolenic acid and the secretion of cholecystokinin (CCK) of a human body can be remarkably increased through unique free fatty acid (FFA).The cholecystokinin has a positive correlation relation with the satiety of the human body; energy intake of organisms is easy to reduce through increasing the secretion of the cholecystokinin.

Disclosed are a method and a corresponding pharmaceutical composition for treating damaged ligaments. Neurogenic compounds in general and neuropeptides in particular have been found to be highly effective in stimulated repair of ligaments damaged due to traumatic injury, ligament disease, and disuse. Preferred active ingredients for use in the method and corresponding pharmaceutical composition include calcitonin gene-related peptide (CGRP), cholecystokinin (CCK), dynorphin, enkephalin, galanin, neuropeptide Y (NPY), neurotensin, somatostatin, substance P (SP), thyrotropin-releasing hormone (TRH), vasoactive intestinal peptide (VIP).

The invention provides a method for diagnosing depression, which comprises the detection of a glutamate acid neural signal in a patient's nucleus accumbens loop, and particularly comprises the detection of a cannabinoid systemic neural signal in the patient's basolateral amygdala-nucleus accumbens loop, for example, the detection of the amount of a type 1 cannabinoid receptor (a CB1 receptor) in cholecystokinin-positive glutamate neurons of the basolateral amygdala. The invention further provides a kit for diagnosing the depression, which comprises a reagent for detecting a glutamate systemicneural signal of the nucleus accumbens loop, in particular the reagent for detecting the cannabinoid systemic neural signal in the basolateral amygdala-nucleus accumbens loop, for example, the reagentfor detecting the amount of the type 1 cannabinoid receptor (the CB1 receptor) in the cholecystokinin-positive glutamate neurons of the basolateral amygdala.

The invention provides a GLP-1 / CCK-1 receptor dual-excitation polypeptide compound. The GLP-1 / CCK-1 receptor dual-excitation polypeptide compound has the effects of promoting weight reduction, reversing insulin resistance and regulating lipid metabolism while more effectively reducing blood sugar. The polypeptide compound provided by the invention has higher GLP-1 receptor agonistic activity than the natural ligand, and also has selective agonistic activity to CCK-1 receptor. The polypeptide compound provided by the invention is stable in chemical property and low in side effect, does not cause acute pancreatitis, and is suitable for being used as an active ingredient of medicines for treating metabolic diseases such as diabetes, obesity, hyperlipidemia, NAFLD and NASH.

Canine CCK1 receptor materials are described, such as polypeptides having amino acid sequences corresponding to SEQ ID Nos.: 14, 15, and 16 or functional variants thereof and polynucleotides expressing them having nucleic acid sequences corresponding to SEQ ID Nos.: 11, 12, and 13 or complements thereof. Such materials are useful as reagents in drug screening assays to identify compounds having CCK1R-modulating activity.